Insights
Search Results
News Articles
1.16.26
Firm Attorneys Named to 2026 Lawdragon 500 Leading Global Antitrust & Competition Lawyers
On January 16, 2026, 15 Wilson Sonsini attorneys were selected for inclusion in Lawdragon’s “500 Leading Antitrust & Global Competition Lawyers” guide. The lawyers featured are recognized for navigating global antitrust regulatory regimes, representing clients in massive competition contests, and navigating frameworks of countries and markets globally.
Bylined Articles
12.02.25
Wilson Sonsini Attorneys Author Competition Policy International Article: "The Evolving Role of Innovation Theories of Harm in the Antitrust Analysis of Life Science Mergers"
Michelle Yost Hale, Matthew D. McDonald, and Merrill Stovroff, attorneys at Wilson Sonsini Goodrich & Rosati, authored a recent Competition Policy International article titled "The Evolving Role of Innovation Theories of Harm in the Antitrust Analysis of Life Science Mergers."
Client Highlights
10.13.25
Wilson Sonsini Advises Fivetran on Merger with dbt Labs
On October 13, 2025, Fivetran, a global leader in automated data movement, announced that it signed a definitive agreement to merge with dbt Labs, a pioneer of modern data transformation, in an all-stock deal. The combined company will be approaching $600 million in annual recurring revenue. The transaction marks significant consolidation in the data tooling market as enterprises race to adapt infrastructure for artificial intelligence applications. Wilson Sonsini Goodrich & Rosati advised Fivetran on the transaction.
Alerts
9.12.25
The Trump FTC Takes New Action Against Non-Competes, While Abandoning Defense of the Biden-Era Non-Compete Clause Rule
Demonstrating its focus on challenging non-competes through case-by-case enforcement, the Federal Trade Commission (FTC) recently undertook a series of actions. It announced a consent decree requiring Gateway Memorial Pet Services (Gateway), the largest pet cremation business in the United States, to immediately cease enforcement of non-compete agreements that the FTC alleged “limit [employee] job mobility and the ability to negotiate better wages and benefits."1 Along with that action, the FTC also issued a broad Request for Information (“RFI”), inviting members of the public to provide information on non-compete agreements that they themselves may be subject to or have knowledge regarding so the FTC can investigate further and bring enforcement action as appropriate. The following day, the FTC announced it would abandon its appeals in Ryan, LLC v. FTC, No. 24-10951 (5th Cir.), and Properties of the Villages v. FTC, No. 24-13102 (11th Cir.), and to accede to the order in Ryan setting aside the Biden-era Non-Compete Clause Rule.
News Articles
7.11.25
Lawdragon Names 12 Wilson Sonsini Lawyers to Its 2025 List of Next-Generation Lawyers
Twelve Wilson Sonsini attorneys have been recognized in the 2025 Lawdragon 500 X – The Next Generation, the third edition of the guide. Individuals listed in the guide traditionally have “proven themselves early in private practice, accruing credentials, deals, and cases early and often,” with the majority of lawyers having been in practice between seven and fifteen years.
Bylined Articles
2.20.25
Weaponizing Antitrust: An Unsubstantiated Attack Against Climate Initiatives
In “Weaponizing Antitrust: An Unsubstantiated Attack Against Climate Initiatives,” an article recently published by Thomson Reuters, Wilson Sonsini partners Jindrich Kloub, Matthew McDonald, Brent Snyder, and Jeff VanHooreweghe discuss how the antitrust attack on climate initiatives is heating up, with 12 states recently filing lawsuits attacking such initiatives under the antitrust laws and the House Judiciary Committee issuing demand letters describing such initiatives as antitrust “cartels.”
In this article, the authors explain why the conduct recently under attack does not violate the antitrust laws as alleged—and that, conversely, the initiatives encourage competition with cleaner, more innovative, or more transparent products.
Click here to read the full article.
In this article, the authors explain why the conduct recently under attack does not violate the antitrust laws as alleged—and that, conversely, the initiatives encourage competition with cleaner, more innovative, or more transparent products.
Click here to read the full article.
Alerts
1.24.25
2025 Year in Preview: Pending Decisions at the U.S. Antitrust Agencies
President Trump has chosen Gail Slater to lead the U.S. Department of Justice (DOJ) Antitrust Division and elevated Commissioner Andrew Ferguson to chair the U.S. Federal Trade Commission (FTC). In this second installment of the Wilson Sonsini Antitrust and Competition practice 2025 Year in Preview four-part series, we review the DOJ and FTC litigations, investigations, and policy decisions they will inherit, focusing on matters where we think a change in direction is most likely. In an appendix, we include all publicly known agency decisions that are pending as of Inauguration Day.
Alerts
1.09.25
Gun-Jumping Violation Results in Record-Breaking Penalties
The Federal Trade Commission (FTC) has imposed a record-breaking $5.6 million fine on XCL Resource Holdings, LLC (XCL), Verdun Oil Company II LLC (Verdun), and EP Energy LLC (EP) to settle allegations that they engaged in unlawful gun-jumping in violation of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act). The enforcement action, which was filed in federal court by the U.S. Department of Justice (DOJ) on January 7, 2025, is a strong reminder that merging parties must continue to operate as independent companies until the HSR waiting period has expired.
Client Highlights
1.08.25
Wilson Sonsini Advises Transcarent on Acquisition of Accolade and Preferred Stock Financing Led by General Catalyst
On January 8, 2025, Transcarent, the “One Place for Health and Care,” and Accolade, a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent will acquire Accolade for $7.03 per share in cash, which represents a total equity value of approximately $621 million. Transcarent will finance the transaction through a fully committed equity financing led by General Catalyst and Glen Tullman’s 62 Ventures. Wilson Sonsini Goodrich & Rosati is advising Transcarent on both the acquisition and the financing.
Client Highlights
12.20.24
Wilson Sonsini Helps Secure EC Clearance of Run:ai’s Acquisition by NVIDIA
On December 20, 2024, the European Commission (EC) unconditionally approved the proposed acquisition of Run:ai Labs by NVIDIA Corporation under the EU Merger Regulation. The EC concluded that the transaction would raise no competition concerns in the European Economic Area (EEA). Wilson Sonsini Goodrich & Rosati represented Run:ai in securing the unconditional clearance.
U.S.-based NVIDIA designs and supplies graphic processing units (GPUs), a type of semiconductor for data center applications. Israel-based Run:ai supplies GPU orchestration software allowing corporate customers to schedule, manage, and optimize their AI compute infrastructure. NVIDIA’s proposed acquisition of Run:ai was notified to the EC on November 15 following a referral request from the Italian national competition authority. The EC investigated the impact of the transaction on the markets for the supply of discrete GPUs for use in data centers and GPU orchestration software. It assessed whether, post-transaction, NVIDIA would be able to hamper the compatibility between its GPUs and the GPU orchestration software of Run:ai’s competitors, and the compatibility between Run:ai’s software and the GPUs of NVIDIA’s competitors. The EC concluded that the proposed acquisition would not raise competition concerns in any of the markets examined in the EEA or Italy, and therefore cleared the transaction unconditionally.
The Wilson Sonsini antitrust team that secured the clearance for Run:ai included Jamillia Ferris, Deirdre Carroll, Michelle Hale, Matthew McDonald, Ben Labow, Kimberley Biagioli, Rachel Burke, Lindsey Edwards, Rose Reinacher, John Sack, Laurine Daïnesi Signoret, Dillon Ostlund, Jacob Lozano, Michelle Zang, Sabin Chung, and Rohena Rajbhandari.
For more information, please see the EC’s announcement.
U.S.-based NVIDIA designs and supplies graphic processing units (GPUs), a type of semiconductor for data center applications. Israel-based Run:ai supplies GPU orchestration software allowing corporate customers to schedule, manage, and optimize their AI compute infrastructure. NVIDIA’s proposed acquisition of Run:ai was notified to the EC on November 15 following a referral request from the Italian national competition authority. The EC investigated the impact of the transaction on the markets for the supply of discrete GPUs for use in data centers and GPU orchestration software. It assessed whether, post-transaction, NVIDIA would be able to hamper the compatibility between its GPUs and the GPU orchestration software of Run:ai’s competitors, and the compatibility between Run:ai’s software and the GPUs of NVIDIA’s competitors. The EC concluded that the proposed acquisition would not raise competition concerns in any of the markets examined in the EEA or Italy, and therefore cleared the transaction unconditionally.
The Wilson Sonsini antitrust team that secured the clearance for Run:ai included Jamillia Ferris, Deirdre Carroll, Michelle Hale, Matthew McDonald, Ben Labow, Kimberley Biagioli, Rachel Burke, Lindsey Edwards, Rose Reinacher, John Sack, Laurine Daïnesi Signoret, Dillon Ostlund, Jacob Lozano, Michelle Zang, Sabin Chung, and Rohena Rajbhandari.
For more information, please see the EC’s announcement.
Client Highlights
12.06.24
Wilson Sonsini Advises Dewpoint Therapeutics on Strategic Research Collaboration with MTPC
On December 4, 2024, Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced that it has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) to advance Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), effective December 1, 2024.